Alterity Therapeutics Issues Shareholder Letter Highlighting

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 -- Alterity...

Related Keywords

Australia , San Francisco , California , United States , Melbourne , Victoria , David Stamler , European Commission , Securities Exchange , Alterity Therapeutics , Vanderbilt University Medical Center , Nasdaq , Preliminary Data , Multiple System Atrophy , Orphan Drug Designation , Chief Executive Officer , Multiple System , Securities Act , Securities Exchange Act , Annual Report , Markets ,